• Je něco špatně v tomto záznamu ?

Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study

S. Gerdes, D. Thaçi, CEM. Griffiths, P. Arenberger, J. Poetzl, G. Wuerth, M. Afonso, H. Woehling,

. 2018 ; 32 (3) : 420-427. [pub] 20171102

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19001169

BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product (ETN, Enbrel® ) and evaluate effects of repeated switching between GP2015 and ETN. Results for efficacy, safety and immunogenicity during treatment period (TP) 2 (TP2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). METHODS: Patients (n = 531) were randomized 1:1 to self-administer GP2015 or ETN twice-weekly subcutaneously during TP1. Patients with a ≥50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were re-randomized for TP2 to continue the same treatment at once-weekly dosing or to undergo three consecutive treatment switches between GP2015 and ETN until week 30. Patients continued the last-assigned treatment during TP2, until week 52. RESULTS: Mean (standard deviation [SD]) PASI scores at baseline were similar in patients who underwent multiple switches compared to those with continued treatments during TP2. During TP2, PASI 50, PASI 75 and PASI 90 response rates, percent change from baseline in PASI scores and all other efficacy parameters were similar between the pooled switched and pooled continued treatment groups at all time points. The incidence of treatment-emergent adverse events including injection site reactions was comparable between the pooled switched (36.7%) and pooled continued (34.9%) groups. None of the patients in either treatment group were positive for binding anti-drug antibodies in TP2. CONCLUSION: Treatment efficacy, safety and immunogenicity were similar between the pooled continued and pooled switched treatments during TP2, indicating that there are no effects in the short term on clinical data of multiple switches between GP2015 and ETN.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19001169
003      
CZ-PrNML
005      
20190122095444.0
007      
ta
008      
190107s2018 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jdv.14605 $2 doi
035    __
$a (PubMed)28960486
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Gerdes, S $u Psoriasis-Center at the Department of Dermatology, Universitaetsklinikum Schleswig-Holstein, Kiel, Germany.
245    10
$a Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study / $c S. Gerdes, D. Thaçi, CEM. Griffiths, P. Arenberger, J. Poetzl, G. Wuerth, M. Afonso, H. Woehling,
520    9_
$a BACKGROUND: EGALITY was a phase III confirmatory efficacy and safety study conducted in patients with plaque-type psoriasis as a part of totality of evidence gathered during the development of GP2015, an etanercept biosimilar. OBJECTIVE: To demonstrate equivalent efficacy and comparable safety and immunogenicity of GP2015 and the etanercept originator product (ETN, Enbrel® ) and evaluate effects of repeated switching between GP2015 and ETN. Results for efficacy, safety and immunogenicity during treatment period (TP) 2 (TP2) are presented pooling the two continued treatment arms (pooled continued) versus the two treatment arms with repeated switches (pooled switched). METHODS: Patients (n = 531) were randomized 1:1 to self-administer GP2015 or ETN twice-weekly subcutaneously during TP1. Patients with a ≥50% improvement in Psoriasis Area and Severity Index (PASI 50) at week 12 were re-randomized for TP2 to continue the same treatment at once-weekly dosing or to undergo three consecutive treatment switches between GP2015 and ETN until week 30. Patients continued the last-assigned treatment during TP2, until week 52. RESULTS: Mean (standard deviation [SD]) PASI scores at baseline were similar in patients who underwent multiple switches compared to those with continued treatments during TP2. During TP2, PASI 50, PASI 75 and PASI 90 response rates, percent change from baseline in PASI scores and all other efficacy parameters were similar between the pooled switched and pooled continued treatment groups at all time points. The incidence of treatment-emergent adverse events including injection site reactions was comparable between the pooled switched (36.7%) and pooled continued (34.9%) groups. None of the patients in either treatment group were positive for binding anti-drug antibodies in TP2. CONCLUSION: Treatment efficacy, safety and immunogenicity were similar between the pooled continued and pooled switched treatments during TP2, indicating that there are no effects in the short term on clinical data of multiple switches between GP2015 and ETN.
650    _2
$a dospělí $7 D000328
650    _2
$a protilátky $x imunologie $7 D000906
650    _2
$a biosimilární léčivé přípravky $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D059451
650    _2
$a chronická nemoc $7 D002908
650    _2
$a dermatologické látky $x aplikace a dávkování $x škodlivé účinky $x imunologie $x terapeutické užití $7 D003879
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a etanercept $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $x terapeutické užití $7 D000068800
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a injekce subkutánní $7 D007279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a psoriáza $x farmakoterapie $x imunologie $7 D011565
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Thaçi, D $u Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany.
700    1_
$a Griffiths, C E M $u Dermatology Centre, Salford Royal Hospital, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
700    1_
$a Arenberger, P $u Department of Dermatology, Charles University, Third Medical Faculty and Faculty Hospital Kralovske Vinohrady, Prague 10, Czech Republic.
700    1_
$a Poetzl, J $u Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.
700    1_
$a Wuerth, G $u Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.
700    1_
$a Afonso, M $u Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.
700    1_
$a Woehling, H $u Global Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology JEADV $x 1468-3083 $g Roč. 32, č. 3 (2018), s. 420-427
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28960486 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190107 $b ABA008
991    __
$a 20190122095703 $b ABA008
999    __
$a ok $b bmc $g 1365077 $s 1039292
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 32 $c 3 $d 420-427 $e 20171102 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
LZP    __
$a Pubmed-20190107

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace